

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:  
**DEAV1997/F146 US CNT**

Applicants:  
**KIRSCHBAUM, et al**

Serial No.  
**09/849,243**

Filing Date:  
**May 7, 2001**

Title of Invention:  
**PURIFICATION OF HIGHER ORDER TRANSCRIPTION COMPLEXES FROM TRANSGENIC NON-HUMAN ANIMALS**

**CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Anne Marie Falk, at 703-872-9306, on Date of Deposit June 16, 2004  
Printed Name of Person Signing Certificate Jonas Pierre, Sr.  
Signature \_\_\_\_\_

**Total Number of Pages Sent: 81**

Attorney: **F. Aaron Dubberley**  
Reg. No. **41,001**  
Group Art Unit: **1632**  
Examiner: **FALK, Anne Marie**

TO: Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of **Aventis Pharmaceuticals Inc.**

- |   |  |
|---|--|
| <input checked="" type="checkbox"/> Supplemental Amendment (1 page) | <input type="checkbox"/> Fee Transmittal             |
| <input checked="" type="checkbox"/> Berglund Thesis (79 pages)      | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input type="checkbox"/> Extension of Time Petition                 | <input type="checkbox"/> Other _____                 |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order      | <input type="checkbox"/> Other _____                 |
| <input type="checkbox"/> Maintenance Fee Transmittal                |  |

**RECEIVED  
CENTRAL FAX CENTER**

**JUN 16 2004**

**OFFICIAL**

Receipt Confirmed:

Signed \_\_\_\_\_

Dated \_\_\_\_\_

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**KIRSCHBAUM, et al.**

Examiner: FALK, Anne Marie

Art Unit: 1632

Application No.: 09/849,243

Filed: May 7, 2001

Title: **PURIFICATION OF HIGHER ORDER  
TRANSCRIPTION COMPLEXES  
FROM TRANSGENIC NON-HUMAN  
ANIMALS**

**TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, on

June 16, 2004

Date of transmission

Signature

**RECEIVED  
CENTRAL FAX CENTER**

**JUN 16 2004**

**SUPPLEMENTAL AMENDMENT**


Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**OFFICIAL**

Sirs:

Applicants submit herewith an additional copy of the Berglund Thesis, which was made of record in parent application 09/084,219. Applicant's previous attorney, Patricia D. Granados, of the firm Heller Ehrman White & McAuliffe promised to submit this additional copy of the Berglund Thesis on page 8 of the Response filed June 4, 2004.

Respectfully submitted,

  
F. Aaron Dubberley, Reg. No. 41,001  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3737  
Telefax (908) 231-2626

Aventis Docket No. DEAV1997/F146 US CNT